Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Portfolio Pulse from
Theratechnologies presented promising data from the PROMISE-US trial at CROI, showing that patients on ibalizumab-containing regimens achieved similar levels of virologic suppression as controls, despite having more severe HIV at baseline.
March 12, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theratechnologies' PROMISE-US trial data shows ibalizumab achieves similar virologic suppression as controls, even in severe HIV cases, potentially boosting investor confidence.
The positive trial results for ibalizumab, a key product for Theratechnologies, suggest potential for increased adoption and sales, likely boosting investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90